Revitensin

Medicine · European Medicines Agency · Germany

What the source publishes

Holder: Pharmasgp Gmbh
Active ingredients: Acidum Hydrofluoricum Dil. D12, Talpa Europaea Dil. D8, Selenium Dil. D12, Graphites Dil. D8, Thallium Metallicum Dil. D12
Routes: Oral Use
Administrative status: listed-as-authorised

Names this record is found by

Complete source data

de:ema:article57:a0e8bdbe2c7ccfc82a9c

{
  "name": "Revitensin",
  "holder": "Pharmasgp Gmbh",
  "routes": [
    "Oral Use"
  ],
  "marketed": null,
  "useDomain": "unknown",
  "databaseDate": "2026-10-09",
  "sourceStatus": null,
  "supplyRegime": null,
  "listingStatus": "listed-as-authorised",
  "targetSpecies": [],
  "sourceRowCount": 1,
  "activeSubstances": [
    "Acidum Hydrofluoricum Dil. D12, Talpa Europaea Dil. D8, Selenium Dil. D12, Graphites Dil. D8, Thallium Metallicum Dil. D12"
  ],
  "documentRevision": "90",
  "documentReference": "EMA/518502/2018",
  "useDomainEvidence": {
    "basis": "unreviewed",
    "field": null,
    "value": null,
    "version": 1,
    "sourceId": "de.ema.article57"
  },
  "patientEligibility": "not-assessed",
  "centrallyAuthorised": false,
  "targetSpeciesStatus": "not-reported",
  "activeSubstancesText": "Acidum Hydrofluoricum Dil. D12, Talpa Europaea Dil. D8, Selenium Dil. D12, Graphites Dil. D8, Thallium Metallicum Dil. D12",
  "administrativeStatus": "unknown",
  "prescriptionCategory": "unknown",
  "prescriptionRequired": null,
  "authorisationTerritory": "Germany",
  "pharmacovigilanceContacts": [
    {
      "email": "nebenwirkungen@hwi-group.de",
      "phone": "+49 7272 7767 0",
      "masterFileLocation": "Germany"
    }
  ]
}

EMA Article 57 product list

Source: European Medicines Agency (EMA), Article 57 product data (EMA/518502/2018), based on data submitted by marketing-authorisation holders.

Retrieved: November 8, 2026
Licence: Publisher terms
Source id: de.ema.article57

Official source

What this source does not establish

Germany has no free, complete official bulk medicine database with PZNs: BfArM’s AMIce public search is interactive only, its § 31b reference database is supplied to commercial users on request, and the GKV-Spitzenverband and BfArM price lists are PDF-only for reasons of usage rights.
EMA’s Article 57 export names every medicinal product authorised in Germany (national, mutual-recognition and decentralised procedures) and every centrally authorised EU product, as submitted by marketing-authorisation holders; submissions can lag an authorisation change.
A record is one product name, active-substance text, route and marketing-authorisation holder. Strengths, forms, packs, PZNs, authorisation numbers and dates are not published, so rows EMA lists more than once for one such product are kept together with their count.
The export publishes no legal category (verschreibungspflichtig, apothekenpflichtig, freiverkäuflich), so the prescription classification stays unknown; listing is not proof of current authorisation, marketing, availability or reimbursement.
Active-substance names are the English xEVMPD names EMA publishes, not German INN spellings.
EMA’s legal notice permits commercial and non-commercial reproduction with acknowledgement of EMA as the source; its exception for third-party content leaves the status of holder-submitted text unconfirmed.

Read this record from your own software

The same record, with every field and its provenance, is one request away. An API key is free and works immediately.

Get your free API key Read the reference

GET /v1/drugs/record

curl -G "https://api.medifontis.com/v1/drugs/record" \
  -H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
  --data-urlencode "country=de" \
  --data-urlencode "sourceId=de.ema.article57" \
  --data-urlencode "id=de:ema:article57:a0e8bdbe2c7ccfc82a9c"